(Registrieren)

DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing

Geschrieben am 10-09-2008

Parsippany, New Jersey (ots/PRNewswire) -

DSM Pharmaceutical Products (DPP) announced today the appointment
of That's Nice LLC as agency of record for marketing services. This
relationship, in effect since June 2008, covers services for this DSM
business group and its three business units: DSM Pharma Chemicals,
DSM Biologics and DSM Pharmaceuticals, Inc.

DSM Pharmaceutical Products offers custom manufacturing for
pharmaceutical chemicals, manufacturing technology and services for
biopharmaceuticals, and secondary manufacturing of both. Guy Tiene,
director of marketing and communications for DSM Pharmaceutical
Products, said, "This requires an integrated communications program
and a wide range of marketing activities."

Kristine Senft, senior vice president of pharmaceutical chemicals
at DSM said, "That's Nice has been in the industry for more than ten
years with a solid reputation among many companies in pharmaceutical
supply. We have already begun work on strategic marketing for DPP,
beginning with an evolution in communications aligned to business
objectives for the CPhI Worldwide 2008 trade show."

Nigel Walker, managing director of That's Nice LLC added "We are
delighted to have been selected as the agency for DSM Pharmaceutical
Products. DPP's position in these markets, and the business units
that uniquely cover such a spectrum of the market, make it a very
appealing challenge that is completely aligned with our services."

About That's Nice LLC

That's Nice LLC, based in New York City, is a full service agency
providing brand and marketing management with value added business
support. It offers a comprehensive range of marketing services and
specializes in integrated branding and marketing, web development
services, and corporate gift and premium sourcing through its
subsidiary, Nice Gift. That's Nice has served the Pharmaceutical
Supply, Fine Chemicals and Life Sciences markets since 1997. For more
information, please visit www.thatsnice.com.

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality
custom contract manufacturing and development services to the
pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical
Products contract manufacturing services include: chemical
development, registered intermediates, registered starting materials,
active ingredients (API's), fermentation, mammalian cell production
of monoclonal antibodies and proteins, formulation development,
clinical trial manufacturing and finished dose form manufacturing of
solids, semi-solids, and scheduled drugs, aseptic liquid and
lyophilized products. More information: www.dsmpharmaceuticals.com

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life
Sciences and Materials Sciences that contribute to the quality of
life. DSM's products and services are used globally in a wide range
of markets and applications, supporting a healthier, more sustainable
and more enjoyable way of life. End markets include human and animal
nutrition and health, personal care, pharmaceuticals, automotive,
coatings and paint, electrics and electronics, life protection and
housing. DSM has annual sales of almost EUR 8.8 billion and employs
some 23,000 people worldwide. The company is headquartered in the
Netherlands, with locations on five continents. DSM is listed on
Euronext Amsterdam. More information: www.dsm.com.

DSM Forward-looking statements

Any forward-looking statements contained in this press release
that involve inherent risks and uncertainties are based on current
expectations, estimates and projections of the management of DSM and
information currently available. The statements involve certain risks
and uncertainties that are difficult to predict and therefore DSM
does not guarantee that its expectations will be realized.
Furthermore, DSM has no obligation to update any statements contained
in this press release.

For further information please contact:
DSM Pharmaceutical Products That's Nice LLC
Guy Tiene Nigel Walker
Director, Marketing & Managing Director
Communications That's Nice LLC
DSM Pharmaceutical Products Tel: +1-212-366-4455
Tel: +1-973-257-8160 nigel@thatsnice.com
guy.tiene@dsm.com
Web site: http://www.thatsnice.com
http://www.dsmpharmaceuticals.com
http://www.dsm.com

ots Originaltext: That's Nice LLC; DSM Pharmaceutical Products
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Guy Tiene Director, Marketing & Communications of DSM Pharmaceutical
Products, +1-973-257-8160, guy.tiene@dsm.com; or Nigel Walker,
Managing Director of That's Nice LLC, +1-212-366-4455,
nigel@thatsnice.com


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

157803

weitere Artikel:
  • Cavotec MSL Group vertraut Verizon Business seine globale Kommunikation an Reading, England (ots/PRNewswire) - - Wechsel zu IP-Telefonie mit Lösungen von Verizon Business Die Cavotec MSL Group, weltweit führend bei Energieversorgungslösungen, strebt den Wechsel zu einem IP-basierten Kommunikationsumfeld an und hat deshalb seine globale Kommunikations-Infrastruktur Verizon Business anvertraut. Eine komplett gemanagte Verizon Private IP-Lösung wird in diesem Zusammenhang für sichere und schnelle Konnektivität zwischen den betrieblichen Einrichtungen von Cavotec MSL rund um die Welt sorgen. Weiter dient sie mehr...

  • GlaxoSmithKline and Cellzome Announce Major Strategic Alliance LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 (ots/PRNewswire) -- - Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates for Inflammatory Diseases Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases. The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors mehr...

  • euro adhoc: DZ BANK AG / Sonstige Kapitalmarkinformation gemäß § 30e WpHG -------------------------------------------------------------------------------- Sonstige Kapitalmarktinformationen gemäß § 30 e WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 10.09.2008 Anleihe: EUR 75.000.000 5,100% Inhaber-Teilschuldverschreibungen von 2008/2009; 1. Aufstockung: von EUR 25.000.000 um EUR 75.000.000 auf EUR 100.000.000 ISIN: DE000DZ1HAJ9; Emission: 4973; Valuta: mehr...

  • Norwegische Anleihen bieten attraktive Renditen Frankfurt am Main (ots) - - Zyklischer Höhepunkt des Leitzinses trotz Inflationsdruck bereits erreicht - Mittelfristig Annäherung an europäisches Zinsniveau zu erwarten - Vermehrt Anzeichen für Aufwertung der Norwegische Krone erkennbar Der Ölpreisboom der vergangenen Monate hat die wirtschaftliche Entwicklung vieler Länder gebremst. Nicht so in Norwegen: Dort kam es in der Folge sogar zu einer konjunkturellen Überhitzung, die - verglichen mit dem übrigen Europa - einen deutlich höheren Inflationsdruck hervorrief. mehr...

  • euro adhoc: DZ BANK AG / Sonstige Kapitalmarkinformation gemäß § 30e WpHG -------------------------------------------------------------------------------- Sonstige Kapitalmarktinformationen gemäß § 30 e WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 10.09.2008 Anleihe: EUR 50.000.000 4,85% Inhaber-Teilschuldverschreibungen von 2008/2008; 4. Aufstockung: von EUR 200.000.000 um EUR 50.000.000 auf EUR 250.000.000 ISIN: DE000DZ1G747; Emission: 4858; Valuta: mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht